隶属于 government of the united states of america
相关临床试验
48
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1972
进行中（未招募）
2
4.2%
已完成
17
35.4%
Enrolling By Invitation
1
2.1%
尚未招募
3
6.3%
招募中
10
20.8%
暂停
1
2.1%
终止
4
8.3%
Unknown
5
10.4%
撤回
5
10.4%
暂无批准数据
- A novel PTSD therapy combining treadmill walking, personalized music, and eye-movement exercises achieved a 26-point average drop on the PTSD Checklist in early results presented at MHSRS 2026. - The therapy, called MATE-3MDR, integrates music and art therapists to help patients create original artwork focused on post-traumatic growth. - All 10 initial completers carried both PTSD and traumatic brain injury, suggesting the approach works for service members managing both conditions simultaneously. - The adapted version runs on a $300–$400 curved gaming monitor, making it affordable and portable for clinic deployment.
- The Association for the Accreditation of Human Research Protection Programs (AAHRPP) has awarded full accreditation to five new entities, including Merck & Co., Inc. and MedStar Health Research Institute. - An additional 21 organizations earned reaccreditation, joining more than 600 entities worldwide committed to AAHRPP's ethical research standards. - AAHRPP President and CEO Elyse I. Summers emphasized that each accreditation strengthens research protections and helps restore public trust in science. - The Uniformed Services University of the Health Sciences, a U.S. government institution, was recognized for sending a "deliberate, powerful message" about its dedication to safe, ethical research.
- OYE Therapeutics received FDA clearance for its Investigational New Drug application for OYE-101, a novel intravenous caffeine formulation designed to reverse general anesthesia and deep sedation effects. - The company completed a $5 million convertible note financing round to support Phase 1 clinical trials and subsequent pivotal studies for the first-in-class therapy. - OYE-101 addresses critical unmet medical needs in perioperative recovery and emergency care, with potential applications for opioid-induced respiratory depression including fentanyl overdose. - The therapy is being developed under a $20 million research collaboration with the U.S. Department of War and military medical institutions for battlefield applications.
- Researchers have developed blood tests that can detect ALS-related molecular signatures up to a decade before symptoms appear, potentially revolutionizing early diagnosis of the devastating neurodegenerative disease. - Two breakthrough studies demonstrate different approaches: one using proteomics analysis achieving over 98% accuracy in distinguishing ALS patients from healthy individuals, and another utilizing cell-free DNA fragments with machine learning models. - The advances could enable earlier clinical trial enrollment, faster diagnosis, and better disease monitoring for ALS patients, who currently face diagnostic delays of months to over a year. - These blood-based biomarkers may also provide insights into other neurological conditions like Parkinson's disease, expanding their potential clinical impact beyond ALS alone.
- A novel vaccine using radiation-killed, whole-cell Chlamydia bacteria protected by an antioxidant has shown promise in mice. - The vaccine significantly increased antibody levels compared to vaccines prepared without the antioxidant, leading to rapid clearance of infection. - Researchers suggest this approach could pave the way for a new generation of effective Chlamydia vaccines to combat this global health challenge.
